Natural Product (NP) Details
General Information of the NP (ID: NP4127) | |||||
---|---|---|---|---|---|
Name |
Daidzein
|
||||
Synonyms |
4',7-Dihydroxyisoflavone; Daidzeol; 7,4'-Dihydroxyisoflavone; 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-; 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one; 7-Hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; UNII-6287WC5J2L; CCRIS 7600; K 251b; 4,7-Dihydroxyisoflavone; EINECS 207-635-4; BRN 0231523; CHEMBL8145; 4',7-Dihydroxy-iso-flavone; d-(+)-alpha-methylbenzylamine; ,7-Dihydroxyisoflavone; 7,4'-dihydroxyisoflavone; DIADZEIN; 486-66-8
Click to Show/Hide
|
||||
Species Origin | Erythrina latissima ... | Click to Show/Hide | |||
Erythrina latissima | |||||
Glycine max | |||||
Medicago sativa | |||||
Trifolium repens | |||||
Trifolium pratense | |||||
Epimedium pubescens | |||||
Pueraria calycina | |||||
Pueraria edulis | |||||
Disease | Diabetic retinopathy [ICD-11: 9B71] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C15H10O4
|
||||
PubChem CID | |||||
Canonical SMILES |
C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O
|
||||
InChI |
1S/C15H10O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-8,16-17H
|
||||
InChIKey |
ZQSIJRDFPHDXIC-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 486-66-8
|
||||
Herb ID | |||||
ETMC ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Topotecan | Ovarian cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | ABCG2 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
In-vivo Model | Adult female athymic nude mice (six-week-old) were injected with MCF7 cells (5*106 cells/mouse) to construct subcutaneous breast cancer xenografts. | |||||
Experimental
Result(s) |
Daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer. | |||||
β. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | NCH89 | CVCL_S823 | Glioblastoma | Homo sapiens | ||
LN-229 | CVCL_0393 | Glioblastoma | Homo sapiens | |||
Experimental
Result(s) |
Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Aldose reductase (AKR1B1) | Molecule Info | [4] | |
Estrogen receptor (ESR) | Molecule Info | [5] | ||
Estrogen-related receptor (ESRR) | Molecule Info | [6] | ||
Transient receptor potential channel 5 (TRPC5) | Molecule Info | [7] | ||
BioCyc | Methylglyoxal degradation III | Click to Show/Hide | ||
2 | Acetone degradation I (to methylglyoxal) | |||
KEGG Pathway | Pentose and glucuronate interconversions | Click to Show/Hide | ||
2 | Fructose and mannose metabolism | |||
3 | Galactose metabolism | |||
4 | Glycerolipid metabolism | |||
5 | Metabolic pathways | |||
6 | Estrogen signaling pathway | |||
7 | Prolactin signaling pathway | |||
8 | Thyroid hormone signaling pathway | |||
9 | Endocrine and other factor-regulated calcium reabsorption | |||
10 | Proteoglycans in cancer | |||
NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
2 | TGF_beta_Receptor Signaling Pathway | |||
3 | FSH Signaling Pathway | |||
4 | EGFR1 Signaling Pathway | |||
5 | RANKL Signaling Pathway | |||
Panther Pathway | Alzheimer disease-presenilin pathway | Click to Show/Hide | ||
Pathwhiz Pathway | Fructose and Mannose Degradation | Click to Show/Hide | ||
2 | Pyruvate Metabolism | |||
3 | Pterine Biosynthesis | |||
4 | Glycerolipid Metabolism | |||
5 | Galactose Metabolism | |||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
2 | Signaling events mediated by HDAC Class II | |||
3 | Plasma membrane estrogen receptor signaling | |||
4 | LKB1 signaling events | |||
5 | Regulation of Telomerase | |||
6 | ATF-2 transcription factor network | |||
7 | AP-1 transcription factor network | |||
8 | FOXM1 transcription factor network | |||
9 | Validated nuclear estrogen receptor alpha network | |||
10 | Signaling mediated by p38-alpha and p38-beta | |||
11 | FOXA1 transcription factor network | |||
Reactome | Nuclear signaling by ERBB4 | Click to Show/Hide | ||
2 | Nuclear Receptor transcription pathway | |||
3 | TRP channels | |||
4 | Role of second messengers in netrin-1 signaling | |||
WikiPathways | Metapathway biotransformation | Click to Show/Hide | ||
2 | Polyol Pathway | |||
3 | Metabolism of steroid hormones and vitamin D | |||
4 | Estrogen signaling pathway | |||
5 | Nuclear Receptors Meta-Pathway | |||
6 | Estrogen Receptor Pathway | |||
7 | Signaling by ERBB4 | |||
8 | JAK/STAT | |||
9 | Integrated Pancreatic Cancer Pathway | |||
10 | Leptin signaling pathway | |||
11 | miR-targeted genes in muscle cell - TarBase | |||
12 | Integrated Breast Cancer Pathway | |||
13 | Nuclear Receptors | |||
14 | Netrin-1 signaling |


